ESR1 and breast cancer: That these tumors are more aggressive is also suggested by recent data using anti-phospho S118 ESR1 to identify cases where the ERα pathway is active; mutation of this site leads to more aggressive cell behavior in MCF7 breast cancer cells ([41] and references therein).